- Home
- KROS vs GLRE Comparison
KROS vs GLRE Comparison
Compare KROS & GLRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KROS | GLRE |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 481.5M |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | KROS | GLRE |
|---|---|---|
| Price | $12.00 | $17.85 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $22.25 | N/A |
| AVG Volume (30 Days) | ★ 482.3K | 231.6K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.00 | 75.00 |
| EPS | ★ 2.30 | 2.17 |
| Revenue | $243,864,000.00 | ★ $729,777,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $727.07 | N/A |
| P/E Ratio | ★ $5.22 | $8.23 |
| Revenue Growth | N/A | ★ 4.85 |
| 52 Week Low | $9.12 | $11.57 |
| 52 Week High | $22.55 | $18.04 |
Technical Indicators
Market Signals| Indicator | KROS | GLRE |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 75.31 |
| Support Level | $10.49 | $12.66 |
| Resistance Level | $15.97 | N/A |
| Average True Range (ATR) | 0.56 | 0.57 |
| MACD | 0.31 | 0.09 |
| Stochastic Oscillator | 98.14 | 92.05 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.